Pilot trial of clenbuterol in spinal and bulbar muscular atrophy
Authors:
- Giorgia QuerinGQGiorgia Querin
- Carla D’ascenzoCDCarla D’ascenzo
- Enrico PeterleEPEnrico Peterle
- Mario ErmaniMEMario Ermani
- Luca BelloLBLuca Bello
- Paola MelaciniPMPaola Melacini
- Lucia MorandiLMLucia Morandi
- Letizia MazziniLMLetizia Mazzini
- Vincenzo SilaniVSVincenzo Silani
- Monika RaimondiMRMonika Raimondi
- Jessica MandrioliJessica Mandrioli
- Silvia RomitoSRSilvia Romito
- 4 June 2013
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (23) , 2095-2098
Abstract
Objective: To test the efficacy and tolerability of clenbuterol in patients with spinal and bulbar muscular atrophy (SBMA). Methods: Twenty patients with a diagnosis of SBMA were given oral clenbuterol (0.04 mg/d) for 12 months. The primary efficacy end point was the change from baseline of the walking distance covered in 6 minutes at 12 months. Secondary end points included the change over time in muscle strength assessed with the Medical Research Council scale, the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), and forced vital capacity values. Safety was assessed by a series of laboratory and instrumental tests, as well as reporting of adverse events. Results: Sixteen patients completed the study. There was a significant and sustained increase in walking distance covered in 6 minutes and forced vital capacity between the baseline and the 12-month assessments (p < 0.001). No differences were recorded in Medical Research Council or ALSFRS-R scores between baseline and follow-up assessments. Serious side effects, including those on heart function, were absent. A significant increase in serum creatine kinase levels was observed. Conclusions: Our findings suggest a positive effect of clenbuterol on SBMA disease progression. Classification of evidence: This study provides Class IV evidence that clenbuterol is effective in improving motor function in SBMA.Keywords
This publication has 10 references indexed in Scilit:
- Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA)Progress in Neurobiology, 2012
- Walking capacity evaluated by the 6‐minute walk test in spinal and bulbar muscular atrophyMuscle & Nerve, 2008
- Role of β-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and DiseasePhysiological Reviews, 2008
- Spinal and bulbar muscular atrophy: Skeletal muscle pathology in male patients and heterozygous femalesJournal of the Neurological Sciences, 2008
- Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicityHuman Molecular Genetics, 2007
- ATS Statement: Guidelines for the Six-Minute Walk TestAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Muscle and serum changes with salbutamol administration in aerobically exercised ratsComparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, 2000
- The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory functionJournal of the Neurological Sciences, 1999
- Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophyNature, 1991
- Selective beta‐adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects [see comments]British Journal of Clinical Pharmacology, 1990